Suzuki Daisuke, Kobayashi Ryoji, Iguchi Akihiro, Sano Hirozumi, Kishimoto Kenji, Yasuda Kazue, Kobayashi Kunihiko
Department of Pediatrics, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishiku, Sapporo, 003-0006, Japan,
Int J Hematol. 2014 Nov;100(5):485-9. doi: 10.1007/s12185-014-1658-z. Epub 2014 Sep 13.
Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterized by seizures, altered mental status and visual disorders, along with characteristic radiological findings. It is strongly related to hypertension induced by steroids and other immunosuppressive agents. There are an increasing number of reports regarding PRES arising during the course of chemotherapy for hematological malignancies. To clarify the risk factors for this phenomenon, we retrospectively analyzed pediatric patients undergoing treatment for hematological malignancies. Of 161 patients, six patients (3.7%) developed PRES with characteristic clinical and radiographic findings. Univariate analysis revealed that tumor lysis syndrome (TLS) was a significant risk factor for the onset of PRES. TLS is a significant risk factor for the development of PRES in pediatric patients receiving chemotherapy for hematological malignancies.
后部可逆性脑病综合征（PRES）是一种神经系统疾病，其特征为癫痫发作、精神状态改变和视觉障碍，以及特征性的影像学表现。它与类固醇和其他免疫抑制剂诱发的高血压密切相关。关于血液系统恶性肿瘤化疗过程中出现PRES的报道越来越多。为了阐明这一现象的危险因素，我们回顾性分析了接受血液系统恶性肿瘤治疗的儿科患者。在161例患者中，6例（3.7%）出现了具有特征性临床和影像学表现的PRES。单因素分析显示，肿瘤溶解综合征（TLS）是PRES发病的一个重要危险因素。TLS是接受血液系统恶性肿瘤化疗的儿科患者发生PRES的一个重要危险因素。
